MTC2 Antibody

What is MTCO2 and why is it an important research target?

MTCO2 (cytochrome c oxidase II) is a mitochondrially-encoded subunit of the respiratory chain that catalyzes electron transfer reactions. As a component of the mitochondrial respiratory complex IV, it plays a crucial role in cellular energy production through oxidative phosphorylation. The protein functions as part of the final electron acceptor in the respiratory chain, making it vital for understanding mitochondrial function, cellular metabolism, and mitochondrial diseases .

Research targeting MTCO2 can provide insights into:

• Mitochondrial respiratory function

• Cellular energy metabolism

• Mitochondrial disorders and dysfunctions

• Cellular responses to metabolic stress

What are the main applications of MTCO2 antibodies in research?

MTCO2 antibodies have demonstrated utility across multiple experimental techniques, with validated applications including:

These applications enable researchers to examine protein expression, localization, and interaction networks involving MTCO2 in various experimental contexts .

How should researchers determine the optimal antibody concentration for their experiment?

Determining optimal antibody concentration requires systematic titration and validation specific to each experimental system. Start with the manufacturer's recommended dilution ranges:

• Prepare a dilution series spanning the recommended range (e.g., for Western blot: 1:5000, 1:10000, 1:25000, 1:50000)

• Run parallel experiments using positive control samples (e.g., HeLa or HepG2 lysates for MTCO2)

• Evaluate signal-to-noise ratio, background levels, and specificity at each concentration

• Select the dilution that provides optimal specific signal with minimal background

• Validate results with appropriate controls (positive, negative, secondary-only)

Remember that optimal concentrations may vary between different experimental techniques and sample types. The observed molecular weight for MTCO2 is typically 23-26 kDa (calculated MW: 26 kDa), which serves as a validation point when optimizing Western blot conditions .

How can researchers differentiate between MTCO2 and other mitochondrial proteins in complex samples?

Differentiating MTCO2 from other mitochondrial proteins requires strategic experimental design:

• Employ subcellular fractionation techniques: Isolate pure mitochondrial fractions using differential centrifugation or commercial kits before antibody-based detection.

• Use co-localization studies: For immunofluorescence applications, combine MTCO2 antibody with established mitochondrial markers (e.g., TOMM20, VDAC1) and examine co-localization patterns through confocal microscopy.

• Validate with functional assays: Complement antibody-based detection with functional assays specific to complex IV activity.

• Implement knockdown/knockout validation: Use MTCO2-targeted siRNA or CRISPR-Cas9 approaches to create negative controls that confirm antibody specificity.

• Consider mass spectrometry validation: For complex samples, immunoprecipitate with MTCO2 antibody and analyze by mass spectrometry to confirm target identity.

When using antibody 83132-7-RR, researchers should be aware of its high specificity for human samples, with validated reactivity across multiple cell lines including HepG2, 143B, HeLa, U-251, A549, and MDA-MB-231 .

What are the key considerations when planning MTCO2 immunohistochemistry studies?

Successful MTCO2 immunohistochemistry requires careful attention to several methodological factors:

• Antigen retrieval optimization: MTCO2 antibodies perform optimally with specific antigen retrieval conditions. For product 83132-7-RR, TE buffer (pH 9.0) is recommended as the primary method, with citrate buffer (pH 6.0) as an alternative . Systematic comparison of both methods may be necessary for specific tissue types.

• Tissue preparation impact: Formalin fixation time critically affects mitochondrial epitope preservation. Standardize fixation protocols (typically 24-48 hours) for consistent results.

• Antibody dilution and incubation parameters: Start with the recommended dilution range (1:500-1:2000 for product 83132-7-RR) and optimize incubation time and temperature (typically 1-2 hours at room temperature or overnight at 4°C) .

• Control selection strategy:

  • Positive controls: Human ovarian cancer, stomach cancer, or colon cancer tissues (validated with specific antibodies)

  • Negative controls: Include secondary-only controls and tissue known to lack MTCO2 expression

• Detection system considerations: Chromogenic systems (DAB) provide good sensitivity, while fluorescent detection offers multiplexing capabilities for co-localization studies.

How should researchers interpret anti-mitochondrial antibody test results in the context of liver pathology research?

Anti-mitochondrial antibodies (AMA) and the M2 subtype are critical serological markers in liver pathology research, particularly for primary biliary cholangitis (PBC). Interpretation requires nuanced understanding of diagnostic accuracy parameters:

A meta-analysis examining AMA diagnostic performance demonstrated:

• Pooled sensitivity: 84% (95% CI: 77-90%)

• Pooled specificity: 98% (95% CI: 96-99%)

• Positive likelihood ratio (LR+): 42.2 (22.1-80.5)

• Negative likelihood ratio (LR-): 0.16 (0.11-0.24)

• Diagnostic odds ratio (DOR): 262 (114-601)

For the M2 subtype specifically:

• Pooled sensitivity: 89% (95% CI: 81-94%)

• Pooled specificity: 96% (95% CI: 93-98%)

• Positive likelihood ratio (LR+): 20.3 (8.0-51.1)

• Negative likelihood ratio (LR-): 0.12 (0.05-0.26)

• Diagnostic odds ratio (DOR): 169 (41-706)

When interpreting results, researchers should consider:

• Testing method influence (IIF vs. ELISA) on sensitivity and specificity

• The presence of AMA-negative PBC variants (approximately 5-10% of cases)

• Clinical correlation with other laboratory parameters (elevated alkaline phosphatase, gamma-glutamyl transferase)

• Histopathological confirmation in research contexts

• Potential overlap with other autoimmune conditions

What are the most effective strategies for optimizing MTCO2 Western blot protocols?

Optimizing MTCO2 Western blot protocols requires attention to several technical parameters:

• Sample preparation refinement:

  • Use RIPA or NP-40 based lysis buffers with protease inhibitors

  • Include reducing agents (β-mercaptoethanol or DTT) in sample buffer

  • Heat samples at 95°C for 5 minutes to denature completely

• Gel selection strategy:

  • Given MTCO2's observed molecular weight (23-26 kDa), use 12-15% acrylamide gels

  • Consider gradient gels (4-20%) for simultaneous detection of multiple proteins

• Transfer optimization:

  • Use PVDF membranes (0.2 μm pore size) for optimal protein binding

  • Implement wet transfer (25V overnight or 100V for 1 hour) for efficient transfer

• Blocking and antibody incubation parameters:

  • Block with 5% non-fat milk or BSA in TBST for 1 hour at room temperature

  • Use antibody at optimal dilution (1:5000-1:50000 for product 83132-7-RR)

  • Incubate primary antibody overnight at 4°C for best results

• Signal development considerations:

  • Enhanced chemiluminescence (ECL) provides sufficient sensitivity

  • Fluorescent secondary antibodies enable more accurate quantification

For challenging samples, concentrate mitochondrial fractions through differential centrifugation before proceeding with standard Western blot protocols to enhance detection sensitivity.

How can researchers effectively use MTCO2 antibodies in immunofluorescence applications?

Successful immunofluorescence with MTCO2 antibodies requires attention to several methodological aspects:

• Cell fixation and permeabilization optimization:

  • 4% paraformaldehyde (10-15 minutes) preserves mitochondrial morphology

  • Permeabilize with 0.1-0.2% Triton X-100 (5-10 minutes) for optimal antibody access to mitochondrial epitopes

  • Alternative: methanol fixation/permeabilization (-20°C, 10 minutes) for specific applications

• Antibody dilution and incubation parameters:

  • Dilute primary antibody optimally (1:200-1:800 for product 83132-7-RR)

  • Incubate overnight at 4°C to maximize signal-to-noise ratio

  • Use fluorophore-conjugated secondary antibodies at 1:500-1:1000 dilution

• Counterstaining strategy:

  • DAPI for nuclear visualization (1 μg/ml, 5 minutes)

  • Consider mitochondrial co-markers (MitoTracker, TOMM20) for validation

  • Mount in anti-fade medium to preserve signal

• Imaging parameters:

  • Confocal microscopy recommended for detailed mitochondrial network analysis

  • Adjust exposure settings to prevent photobleaching

  • Establish Z-stacks for three-dimensional mitochondrial network analysis

HepG2 cells serve as positive controls for MTCO2 immunofluorescence applications, consistently demonstrating characteristic mitochondrial network patterning .

What are the optimal conditions for MTCO2 antibody-based immunoprecipitation experiments?

Immunoprecipitation with MTCO2 antibodies requires optimized conditions for successful protein complex isolation:

• Lysis buffer selection:

  • Use non-denaturing buffers containing 1% NP-40 or 0.5% Triton X-100

  • Include protease inhibitors, phosphatase inhibitors, and 1-2 mM EDTA

  • Maintain physiological pH (7.4) to preserve protein-protein interactions

• Antibody amount and pre-clearing strategy:

  • Use 0.5-4.0 μg antibody per 1.0-3.0 mg of total protein lysate

  • Pre-clear lysates with Protein A/G beads (1 hour, 4°C) to reduce non-specific binding

  • Pre-couple antibody to beads (2-4 hours, 4°C) before adding to pre-cleared lysate

• Incubation parameters:

  • Perform immunoprecipitation overnight at 4°C with gentle rotation

  • Include IgG isotype control (Rabbit IgG for product 83132-7-RR)

  • Reserve 5-10% of input lysate for comparison in Western blot analysis

• Washing and elution optimization:

  • Wash 4-5 times with cold lysis buffer containing reduced detergent (0.1-0.2%)

  • Elute with SDS sample buffer (95°C, 5 minutes) for standard applications

  • Consider native elution (competition with immunogenic peptide) for functional studies

• Validation approach:

  • Confirm MTCO2 presence in immunoprecipitates via Western blot

  • Identify interacting partners through mass spectrometry analysis

  • Validate novel interactions with reciprocal immunoprecipitation

HeLa cells serve as validated positive controls for MTCO2 immunoprecipitation applications .

What are the relative advantages of different methods for generating MTCO2-specific monoclonal antibodies?

Two major strategies exist for generating antigen-specific human monoclonal antibodies, each with distinct advantages for MTCO2 research:

• Single cell sequencing of antigen-binding B cells:

  • Enables direct isolation of B cells recognizing MTCO2 epitopes

  • Provides comprehensive genetic information about antibody variable regions

  • Allows rapid identification of multiple antibody candidates simultaneously

  • Facilitates structure-function relationship studies through sequence analysis

• Establishment of EBV-immortalized B cell lines:

  • Creates stable, long-term antibody-producing cell lines

  • Allows continuous production without recombinant expression systems

  • Enables functional screening before genetic characterization

  • Preserves native antibody pairing of heavy and light chains

Comparative analysis reveals trade-offs between these approaches:

• Single cell sequencing offers higher throughput but requires sophisticated equipment

• EBV immortalization has lower initial throughput but creates renewable antibody sources

• Both methods can achieve similar specificity when properly executed

• Recovery rates vary between methods, with single cell approaches typically yielding more candidates initially

These approaches can be applied to generate MTCO2-specific antibodies for specialized research applications not addressed by commercial offerings.

How can researchers evaluate and address potential cross-reactivity in MTCO2 antibody applications?

Evaluating and mitigating cross-reactivity is essential for reliable MTCO2 antibody applications:

• Systematic cross-reactivity assessment:

  • Test against tissues/cells known to lack MTCO2 expression

  • Evaluate reactivity in knockout/knockdown models where available

  • Perform peptide competition assays with immunizing peptide

  • Compare staining patterns across multiple antibody clones targeting different MTCO2 epitopes

• Bioinformatic prediction approaches:

  • Analyze immunizing peptide sequence for homology to other proteins

  • Identify potential cross-reactive epitopes through sequence alignment

  • Predict potential conformational mimicry through structural analysis

• Experimental validation strategies:

  • Western blot analysis to confirm single band at expected molecular weight (23-26 kDa)

  • Mass spectrometry validation of immunoprecipitated proteins

  • Dual-staining approaches with antibodies targeting different epitopes

• Mitigation strategies for detected cross-reactivity:

  • Increase antibody dilution to favor high-affinity specific binding

  • Modify blocking conditions (5% BSA vs. 5% milk) to reduce non-specific interactions

  • Implement additional washing steps with increased stringency

  • Consider alternative antibody clones if cross-reactivity cannot be eliminated

For recombinant antibodies like product 83132-7-RR, cross-reactivity is typically lower than for polyclonal alternatives, but validation remains essential for each experimental system .